{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:21:11Z","timestamp":1768260071027,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female\/male ratio\u2009=\u20092:1) in Italy. For most of the patients (67%), the disease course is relapsing\u2013remitting MS (RRMS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS na\u00efve patients vs. RRMS patients previously treated (experienced) with other disease-modifying therapies in Italy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A four health states Markov model-supported cost-utility analysis (CUA) covering a 7-year timespan through annual cycles was developed, following the healthcare sector and the societal viewpoints. Part of the parameters that populated the Markov model was obtained from a questionnaire administered to four primary Italian MS centres. Costs of healthcare and non-healthcare resources, expressed in euro (\u20ac) 2019, and QALYs were discounted at 3% real social discount rate. One-way, scenario and probabilistic sensitivity analyses tested the uncertainty of the baseline findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline CUA shows that teriflunomide in RRMS na\u00efve patients is strongly dominant vs. experienced patients (healthcare sector perspective:\u2009\u2212\u2009\u20ac1042.68 and\u2009+\u20090.480 QALYs; societal perspective:\u2009\u2212\u2009\u20ac6782.81 and\u2009+\u20090.480 QALYs). Sensitivity analyses confirmed the robustness of the baseline results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Teriflunomide in RRMS na\u00efve vs. experienced patients is cost-effective and possibly strongly dominant from both the healthcare sector and the society viewpoints in Italy. Our findings need further confirmation from real-world studies.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10072-022-06022-x","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:03:14Z","timestamp":1649926994000},"page":"4933-4944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-utility analysis of teriflunomide in na\u00efve vs. previously treated patients with relapsing\u2013remitting multiple sclerosis in Italy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-1834","authenticated-orcid":false,"given":"Carlo","family":"Lazzaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-511X","authenticated-orcid":false,"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-934X","authenticated-orcid":false,"given":"Mauro","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-7743","authenticated-orcid":false,"given":"Rocco","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1763","authenticated-orcid":false,"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"6022_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10072-016-2801-9","volume":"38","author":"MA Battaglia","year":"2017","unstructured":"Battaglia MA, Bezzin D (2017) Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci 38:473\u2013479. https:\/\/doi.org\/10.1007\/s10072-016-2801-9","journal-title":"Neurol Sci"},{"key":"6022_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10072-018-3610-0","volume":"40","author":"M Trojano","year":"2019","unstructured":"Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA, Italian Multiple Sclerosis Register Centers Group (2019) The Italian multiple sclerosis register. Neurol Sci 40:155\u2013165. https:\/\/doi.org\/10.1007\/s10072-018-3610-0","journal-title":"Neurol Sci"},{"key":"6022_CR3","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University Press, Oxford","edition":"4"},{"key":"6022_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ane.12705","volume":"136","author":"UK Zettl","year":"2017","unstructured":"Zettl UK, Schreiber H, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M, BETAPATH Study Group (2017) Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. Acta Neurol Scand 136:116\u2013121. https:\/\/doi.org\/10.1111\/ane.12705","journal-title":"Acta Neurol Scand"},{"key":"6022_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40263-019-00691-7","volume":"34","author":"D Paolicelli","year":"2020","unstructured":"Paolicelli D, Manni A, Iaffaldano A, Trojano M (2020) Efficacy and safety of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 34:65\u201392. https:\/\/doi.org\/10.1007\/s40263-019-00691-7","journal-title":"CNS Drugs"},{"key":"6022_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg SP (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389:1347\u20131356. https:\/\/doi.org\/10.1016\/S0140-6736(16)32388-1","journal-title":"Lancet"},{"key":"6022_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS, TEMSO Trial Group (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"6022_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247\u2013256. https:\/\/doi.org\/10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"key":"6022_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","volume":"13","author":"AE Miller","year":"2014","unstructured":"Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O\u2019Connor PW, TOPIC Study Group (2014) Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:977\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(14)70191-7","journal-title":"Lancet Neurol"},{"key":"6022_CR10","unstructured":"Agenzia Italiana del Farmaco. Determina 31 luglio 2014. Regime di rimborsabilita\u2019 e prezzo del medicinale per uso umano \u00abAubagio\u00bb (teriflunomide). (Determina n. 837\/2014) (2014) Gazzetta Ufficiale della Repubblica Italiana, Serie Generale, n. 187 del 13 agosto 2014 (Italian)"},{"key":"6022_CR11","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liao Q, Wen H, Zhang Y (2021) Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev 20:102826. https:\/\/doi.org\/10.1016\/j.autrev.2021.102826","journal-title":"Autoimmun Rev"},{"key":"6022_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40263-016-0377-9","volume":"30","author":"D Mendes","year":"2016","unstructured":"Mendes D, Alves C, Batel-Marques F (2016) Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis. CNS Drugs 30:909\u2013929. https:\/\/doi.org\/10.1007\/s40263-016-0377-9","journal-title":"CNS Drugs"},{"key":"6022_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322\u2013339. https:\/\/doi.org\/10.1177\/0272989X9301300409","journal-title":"Med Decis Making"},{"key":"6022_CR14","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford"},{"key":"6022_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/0470033312","volume-title":"Uncertain judgements: eliciting experts\u2019 probabilities","author":"A O\u2019Hagan","year":"2006","unstructured":"O\u2019Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, Oakley JE, Rakow T (2006) Uncertain judgements: eliciting experts\u2019 probabilities. Wiley, Chichester"},{"key":"6022_CR16","volume-title":"Sampling: design and analysis","author":"SL Lohr","year":"2010","unstructured":"Lohr SL (2010) Sampling: design and analysis, 2nd edn. Brooks\/Cole, Boston","edition":"2"},{"key":"6022_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"6022_CR18","doi-asserted-by":"publisher","unstructured":"Iannazzo S, Santoni L, Saleri C, Puma E, Vestri G, Giuliani L, Canonico PL, Centonze D (2016) Analisi di costo-efficacia dell\u2019utilizzo di peginterferone beta-1a nel trattamento della sclerosi multipla recidivante remittente in Italia. Farmeconomia. Health Econ Ther Pathways 17(Suppl 2):13\u201336. (Italian). https:\/\/doi.org\/10.7175\/fe.v17i2S.1230","DOI":"10.7175\/fe.v17i2S.1230"},{"key":"6022_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12883-017-0927-x","volume":"17","author":"M Stoppe","year":"2017","unstructured":"Stoppe M, Busch M, Krizek L, Then Bergh F (2017) Outcome of MS relapses in the era of disease-modifying therapy. BMC Neurol 17:151. https:\/\/doi.org\/10.1186\/s12883-017-0927-x","journal-title":"BMC Neurol"},{"key":"6022_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R (2007) The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 10:54\u201360. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00144.x","journal-title":"Value Health"},{"key":"6022_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1524-6175.2002.00970.x","volume":"4","author":"JD Stein","year":"2002","unstructured":"Stein JD, Brown GC, Brown MM, Sharma S, Hollands H, Stein HD (2002) The quality of life of patients with hypertension. J Clin Hypertens 4:181\u2013188. https:\/\/doi.org\/10.1111\/j.1524-6175.2002.00970.x","journal-title":"J Clin Hypertens"},{"key":"6022_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Teriflunomide for treating relapsing\u2013remitting multiple sclerosis. Technology appraisal guidance. nice.org.uk\/guidance\/ta303. Accessed 3 Dec 2019"},{"key":"6022_CR23","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11136-017-1536-2","volume":"26","author":"S Kolovos","year":"2017","unstructured":"Kolovos S, Bosmans JE, van Dongen JM, van Esveld B, Magai D, van Straten A, van der Feltz-Cornelis C, van Steenbergen-Weijenburg KM, Huijbregts KM, van Marwijk H, Riper H, van Tulder MW (2017) Utility scores for different health states related to depression: individual participant data analysis. Qual Life Res 26:1649\u20131658. https:\/\/doi.org\/10.1007\/s11136-017-1536-2","journal-title":"Qual Life Res"},{"key":"6022_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14737167.2018.1464394","volume":"18","author":"C Lazzaro","year":"2018","unstructured":"Lazzaro C, Barone C, Caprioni F, Cascinu S, Falcone A, Maiello E, Milella M, Pinto C, Reni M, Tortora G (2018) An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Rev Pharmacoecon Outcomes Res 18:435\u2013446. https:\/\/doi.org\/10.1080\/14737167.2018.1464394","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"6022_CR25","unstructured":"Ministero della Salute. Decreto 8 febbraio 2013. Criteri per la composizione e il funzionamento dei comitati etici. (13A03474) (2013) Gazzetta Ufficiale della Repubblica Italiana, Serie Generale, n. 96 del 24 aprile 2013 (Italian)"},{"key":"6022_CR26","unstructured":"Repubblica Italiana. Legge 23 dicembre 1996, n. 662. Misure di razionalizzazione della finanza pubblica (1996) Supplemento ordinario n. 233 alla Gazzetta Ufficiale della Repubblica Italiana, Serie Generale, n. 303 del 28 dicembre 1996 (Italian)"},{"key":"6022_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/oso\/9780192631770.003.0004","volume-title":"Economic evaluation in health care: merging theory with practice","author":"W Brouwer","year":"2001","unstructured":"Brouwer W, Rutten F, Koopmanschap M (2001) Costing in economic evaluations. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford, pp 68\u201393"},{"key":"6022_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J","volume":"5","author":"J Posnett","year":"1996","unstructured":"Posnett J, Jan S (1996) Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5:13\u201323.\u00a0https:\/\/doi.org\/10.1002\/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J","journal-title":"Health Econ"},{"key":"6022_CR29","doi-asserted-by":"publisher","unstructured":"Fattore G per Gruppo di lavoro Associazione Italiana di Economia Sanitaria (AIES) (2009) Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics \u2013 Italian Research Articles 11:83\u201393 (Italian). https:\/\/doi.org\/10.1007\/BF03320660","DOI":"10.1007\/BF03320660"},{"key":"6022_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10:779\u2013787. https:\/\/doi.org\/10.1002\/hec.635","journal-title":"Health Econ"},{"key":"6022_CR31","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2015","unstructured":"Glick HA, Doshi JA, Sonnad SA, Polsky D (2015) Economic evaluation in clinical trials, 2nd edn. Oxford University Press, Oxford","edition":"2"},{"key":"6022_CR32","unstructured":"Couto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M. Medicines used for multiple sclerosis \u2013 a health technology assessment. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482112\/pdf\/Bookshelf_NBK482112.pdf. Accessed 26 Nov 2019"},{"key":"6022_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","volume":"6","author":"A Boster","year":"2017","unstructured":"Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A (2017) Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol Ther 6:91\u2013102. https:\/\/doi.org\/10.1007\/s40120-017-0064-x","journal-title":"Neurol Ther"},{"key":"6022_CR34","doi-asserted-by":"publisher","first-page":"205521731881903","DOI":"10.1177\/2055217318819031","volume":"4","author":"JD Bowen","year":"2018","unstructured":"Bowen JD, Kozma CM, Grosso MM, Phillips AL (2018) A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Mult Scler J Exp Transl Clin 4:2055217318819031. https:\/\/doi.org\/10.1177\/2055217318819031","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"6022_CR35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","volume":"32","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ (2018) Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs 32:1145\u20131157. https:\/\/doi.org\/10.1007\/s40263-018-0566-9","journal-title":"CNS Drugs"},{"key":"6022_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40261-019-00750-3","volume":"39","author":"Y Xu","year":"2019","unstructured":"Xu Y, Mao N, Chirikov V, Du F, Yeh YC, Liu L, Liu R, Gao X (2019) Cost-effectiveness of teriflunomide compared to interferon beta1b for relapsing multiple sclerosis patients in China. Clin Drug Investig 39:331\u2013340. https:\/\/doi.org\/10.1007\/s40261-019-00750-3","journal-title":"Clin Drug Investig"},{"key":"6022_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force (2012) Modeling good research practices \u2013 overview: a report of the ISPOR SMDM Modeling Good Research Practices Task Force-1. Value Health 15:796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012","journal-title":"Value Health"},{"key":"6022_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR, ISPOR Task Force on Good Research Practices--Modeling Studies (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6:9\u201317. https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00234.x","journal-title":"Value Health"},{"key":"6022_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CEOR.S98226","volume":"8","author":"A Mozzi","year":"2016","unstructured":"Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G (2016) A comparison of EQ-5D health-related utilities using Italian, UK, and US preference weights in a patients sample. Clinicoecon Outcomes Res 8:267\u2013274. https:\/\/doi.org\/10.2147\/CEOR.S98226","journal-title":"Clinicoecon Outcomes Res"},{"key":"6022_CR40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/0272989X20951782","volume":"40","author":"LS Matza","year":"2020","unstructured":"Matza LS, Phillips G, Dewitt B, Stewart KD, Cella D, Feeny D, Hanmer J, Miller DM, Revicki DA (2020) A scoring algorithm for deriving utility values from the neuro-QoL for patients with multiple sclerosis. Med Decis Making 40:897\u2013911. https:\/\/doi.org\/10.1177\/0272989X20951782","journal-title":"Med Decis Making"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:19:36Z","timestamp":1700439576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6022"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06022-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"4 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"During the past 3\u00a0years, CL has received research grants, speaker or consultancy fees from AstraZeneca S.p.A., Boehringer Ingelheim Italia S.p.A., CSL Behring S.p.A., Ferring S.p.A., Ipsen S.p.A., Roche S.p.A., Sanofi S.r.l., Santen GmbH, Shire S.p.A, Sobi S.p.A.RB has served on scientific advisory boards for Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received research support from Almirall, Bayer, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received support for travel and congress from Biogen, Roche, Merck-Serono, Sanofi-Genzyme, Teva; received honoraria for speaking engagement from Biogen, Merck-Serono, Novartis, Sanofi-Genzyme.MZ has served on scientific advisory boards and received honoraria for speaking or support for travel and congress attendance from Almirall, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme.During the past 3\u00a0years, RT has received speaker or consultancy fees from Biogen, Merck-Serono, Novartis, Roche, Sanofi and Teva.DP has received honoraria for consultancy and\/or speaking from Biogen Idec, Merck-Serono, Bayer-Schering, Sanofi-Aventis, TEVA, Novartis and Genzyme.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}